20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) posted results of the Phase 1 trial of Amilo-5MER in healthy volunteers.
- Amilo-5MER is a synthetic peptide consisting of 5 amino acids that significantly reduces symptoms and histopathological hallmarks of Inflammatory bowel disease (IBD) in animal models (TNBS, DSS).
- TNBS and DSS are well-established and widely recognized models of acute colitis.
- Related: Galmed's NASH Candidate Shows Clinically Significant Effect On Fibrosis Improvement.
- Amilo-5MER also showed anti-inflammatory effects in animal models of multiple sclerosis and rheumatoid arthritis.
- Amilo-5MER binds with high affinity to pro-inflammatory amyloid proteins, preventing polymerization of Serum Amyloid A (SAA) monomers and thereby interfering with SAA-induced immune cell activation.
- All doses of Amilo-5MER were well tolerated with no clinically significant adverse events, and none considered related to the investigational product.
- The company plans to submit an IND for mild to moderate ulcerative colitis in 2022.
- Price Action: GLMD shares are down 10.9% at $1.68 during the premarket session on Monday's last check.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!